Shares in Ocular Therapeutix (NSDQ:OCUL) surged this morning after the biopharmaceutical company met expectations on Wall Street with its 3rd-quarter results and announced it will re-submit its new drug application to the FDA for Dextenza, its post-surgical ocular pain reliever, by the end of the year.
In July, the FDA denied approval for Ocular’s hydrogel plug designed to deliver a sustained dosage of dexamethasone over 4 weeks following ophthalmic surgery.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix plans FDA re-submission for Dextenza by end of year, earnings appeared first on MassDevice.
from MassDevice http://www.massdevice.com/ocular-therapeutix-plans-fda-re-submission-dextenza-end-year-earnings/
Cap comentari:
Publica un comentari a l'entrada